Whelton A
Johns Hopkins University, Baltimore, Md.
Cardiology. 1991;79 Suppl 1:10-5. doi: 10.1159/000174901.
We have conducted a multicentre study in patients with mild to moderate hypertension. Lisinopril monotherapy, 10, 20, or 40 mg once daily (n = 35), was compared with captopril monotherapy, 25, 50, or 100 mg twice daily (n = 35). Blood pressure assessments were conducted using both office and 24-hour ambulatory blood pressure monitoring. Area under the curve analysis of ambulatory blood pressure reductions demonstrated significant differences between once-daily lisinopril and twice-daily captopril, with lisinopril producing the most significant reduction in pressure. These therapeutic results reflect the clinical-pharmacological profile of these two angiotensin-converting enzyme inhibitors and provide important clinical implications.
我们对轻至中度高血压患者进行了一项多中心研究。将赖诺普利单药治疗（每日一次，10毫克、20毫克或40毫克，n = 35）与卡托普利单药治疗（每日两次，25毫克、50毫克或100毫克，n = 35）进行比较。使用诊室血压测量和24小时动态血压监测进行血压评估。动态血压降低的曲线下面积分析表明，每日一次的赖诺普利和每日两次的卡托普利之间存在显著差异，赖诺普利使血压降低最为显著。这些治疗结果反映了这两种血管紧张素转换酶抑制剂的临床药理学特征，并提供了重要的临床启示。
